Moderna(MRNA)
CAMBRIDGE, MA
Biotechnology17 H-1B visas (FY2023)Focus: RNA Therapies
Moderna Therapeutics is a life sciences company focused on RNA Therapies.
VaccinesOncologyRare DiseasesInfectious Disease
Funding Stage
PUBLIC
Employees
5,900
Open Jobs
160
Products & Portfolio (3)
Pipeline & Clinical Trials
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccin
MyocarditisClinical Trials (1)
NCT06189053A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
N/AA Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
SARS-CoV-2Clinical Trials (1)
NCT05366322A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
N/AA Retrospective Study to Characterize Participants With Propionic Acidemia
Propionic AcidemiaClinical Trials (1)
NCT05769621A Retrospective Study to Characterize Participants With Propionic Acidemia
N/APost-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-127
SARS-CoV-2Clinical Trials (1)
NCT04958954Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
N/ASPIKEVAX Bivalent
SARS-CoV-2Clinical Trials (1)
NCT06333704Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.
N/ACMV PCR on saliva
Cytomegalovirus InfectionsClinical Trials (1)
NCT06522880Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
N/AmRNA-1345
Respiratory Syncytial VirusClinical Trials (1)
NCT05572658Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
N/APost-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2
SARS-CoV-2Clinical Trials (1)
NCT05894590Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
N/AModerna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
SARS-CoV-2Clinical Trials (1)
NCT04958304Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
N/AA Study of the Effectiveness of Moderna COVID-19 Vaccine
SARS-CoV-2Clinical Trials (1)
NCT05933304A Study of the Effectiveness of Moderna COVID-19 Vaccine
N/AmRNA-1273
Covid19Clinical Trials (1)
NCT05054218COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
N/APatient letter and clinician communication
COVID-19 ImmunisationClinical Trials (1)
NCT06646406Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate
N/APost-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrom
SARS-CoV-2Clinical Trials (1)
NCT05894499Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
N/ASPIKEVAX
SARS-CoV-2Clinical Trials (1)
NCT06130345Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
N/ANo intervention
SARS-CoV-2 InfectionClinical Trials (1)
NCT05794412Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study
N/AA Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
SARS-CoV-2Clinical Trials (1)
NCT05367908A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
N/AmRNA-1273
Myocarditis, PericarditisClinical Trials (1)
NCT06113692A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
N/AWireless wearable digital devices
Healthy ParticipantsClinical Trials (1)
NCT05440318Use of Wearable Digital Sensors After mRNA Vaccination in Adults
N/APost-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe
SARS-CoV-2Clinical Trials (1)
NCT05894525Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
N/ACOVID-19 Vaccine
Coronavirus Disease (COVID-19)Clinical Trials (1)
NCT04941144Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
N/A"The MaP Study": Mapping the Patient Journey in MMA and PA
Methylmalonic AcidemiaClinical Trials (1)
NCT03484767"The MaP Study": Mapping the Patient Journey in MMA and PA
N/AModerna COVID-19 Vaccine
COVID-19Clinical Trials (1)
NCT05765578An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
N/APatient Reported Outcomes
Multiple MyelomaClinical Trials (1)
NCT05831787COVID19 OutcomeS in Myeloma and the Impact of VaCcines
N/AStudy to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
Maternal OutcomesClinical Trials (1)
NCT06369272Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
N/APhase 1
Clinical Trials (1)
NCT03829384Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
Phase 1mRNA-1345
Respiratory Syncytial VirusClinical Trials (1)
NCT05743881A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Phase 1mRNA-1647
Cytomegalovirus InfectionClinical Trials (1)
NCT05105048A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
Phase 1mRNA-1273
COVID-19Clinical Trials (1)
NCT04785144Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
Phase 1V941
NeoplasmsClinical Trials (1)
NCT03948763A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Phase 1Pembrolizumab
Carcinoma, Intraductal, NoninfiltratingClinical Trials (1)
NCT02872025Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
Phase 1mRNA-6231
Healthy VolunteersClinical Trials (1)
NCT04916431A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults
Phase 1mRNA-4106
Advanced Solid TumorsClinical Trials (1)
NCT06880549A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT04144348Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
Phase 1mRNA-0184
Healthy ParticipantsClinical Trials (1)
NCT06655870A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants
Phase 1VAL-181388
Chikungunya VirusClinical Trials (1)
NCT03325075Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
Phase 1mRNA-1893
Zika VirusClinical Trials (1)
NCT04064905Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
Phase 1mRNA -1215
Nipah Virus InfectionClinical Trials (1)
NCT05398796Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
Phase 1mRNA-0184
Healthy ParticipantsClinical Trials (1)
NCT06243770Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants
Phase 1Phase 1
Clinical Trials (1)
NCT05918250mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1mRNA-1010
SARS-CoV-2Clinical Trials (1)
NCT05585632A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
Phase 1mRNA-1645-eODGT8
HIV InfectionsClinical Trials (1)
NCT06694753Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.
Phase 1mRNA-4157
Solid TumorsClinical Trials (1)
NCT03313778Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Phase 1mRNA-1345
Respiratory Syncytial VirusClinical Trials (1)
NCT04528719A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
Phase 1mRNA-1195.1
Epstein-Barr Virus InfectionClinical Trials (1)
NCT05831111A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
Phase 1mRNA-0184
Chronic Heart FailureClinical Trials (1)
NCT05659264A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure
Phase 1mRNA-1325
Zika VirusClinical Trials (1)
NCT03014089Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
Phase 1mRNA-1283
SARS-CoV-2Clinical Trials (1)
NCT04813796A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
Phase 1VAL-339851
InfluenzaClinical Trials (1)
NCT03345043Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
Phase 1mRNA-1273
COVID-19Clinical Trials (1)
NCT04283461Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
Phase 1Clinical Trials (1)
NCT03739931Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
Phase 1Open Jobs (160)
Principal GxP Product Manager
Cambridge, Massachusetts
23h ago
$159K - $286K/yr
MESH Customer Data Steward US Commercial, Trade & Fulfillment
Warsaw - Poland
23h ago
Senior Principal Enterprise AI Solution Engineer
Cambridge, Massachusetts
Yesterday
$184K - $330K/yr
Engineer III, Manufacturing Execution Systems
Norwood, Massachusetts
Yesterday
$100K - $161K/yr
2026 Intern, Biostatistics and Programming
Cambridge, Massachusetts
Yesterday
Engineer I, Manufacturing Execution Systems
Norwood, Massachusetts
Yesterday
$72K - $114K/yr
2026 Co-Op, Analytical Technical Operations
Norwood, Massachusetts
Yesterday
Associate Director, Commercial Operations (Trade Operations)
USA - New Jersey - Princeton - 5 Vaughn Drive
2d ago
$143K - $257K/yr
Associate Director, Commercial Operations (Trade Operations)
Princeton, New Jersey
2d ago
$143K - $257K/yr
2026 Co-Op, Immuno-Oncology Research
Cambridge, Massachusetts
4d ago
2026 Co-Op, Immuno-Oncology Research
Cambridge, Massachusetts
4d ago
2026 Co-Op, Immuno-Oncology Research
Cambridge, Massachusetts
4d ago
Regional Account Manager – Baltimore, MD
Remote
4d ago
$143K - $257K/yr
2026 Co-op, Epidemiology
Cambridge, Massachusetts
5d ago
2026 Co-op, R&D Quality (GxP)
Norwood, Massachusetts
5d ago
2026 Co-op, Statistical AI/ML Research & Agent Enablement
Cambridge, Massachusetts
5d ago
2026 Co-Op, Supply Chain- Logistics Engineering
Norwood, Massachusetts
5d ago
2026 Co-op, Statistical AI/ML Research & Agent Enablement
Cambridge, Massachusetts
5d ago
Director, Cancer Vaccine Research
Cambridge, Massachusetts
1w ago
$167K - $301K/yr
2026 Co-Op, Process Chemistry and Development, Analytical Development
Norwood, Massachusetts
1w ago
CQV Engineer II
Norwood, Massachusetts
1w ago
$74K - $118K/yr
2026 Co-Op, Process Chemistry and Development, Analytical Development
Norwood, Massachusetts
1w ago
Senior Systems Engineer, Digital for Research and Technical Development
Cambridge, Massachusetts
1w ago
$131K - $209K/yr
2026 Co-op, Good Laboratory Practice / Good Clinical Practice
Cambridge, Massachusetts
1w ago
2026 Co-Op, BM Ops/ PBMC Ops
Cambridge, Massachusetts
1w ago
Interview Prep Quick Facts
Founded: 2010
Portfolio: 3 approved products, 132 clinical trials
Top TAs: Infectious Diseases, Oncology, Respiratory
H-1B (2023): 17 approvals
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 160 active jobs
Portfolio Health
Launch2 (67%)
Growth1 (33%)
3 total products
Therapeutic Area Focus
Infectious Diseases
37 pipeline
Oncology
20 pipeline
Respiratory
11 pipeline
Rare Diseases
2 pipeline
Gastroenterology
2 pipeline
Neurology
1 pipeline
Cardiovascular
1 pipeline
Marketed
Pipeline
Financials (FY2025)
Revenue
$6.8B64%
R&D Spend
$4.8B(71%)47%
Net Income
-$4.7BCash
$2.9BHiring Trend
Actively Hiring
160
Open Roles
+124
Added
-4
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
17
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub